Pfizer Cholesterol Flops Cleared Path for Resverlogix

Posted on March 8th, 2010 by Kelley Luckstein

Resverlogix Corp., without a marketed product, may accomplish what Pfizer Inc., the world’s biggest drugmaker, couldn’t: Creating a new medicine that fights heart disease by raising so-called good cholesterol…

 

Resverlogix is banking that artificially raising HDL will have the same effect. Only one treatment now commercially available is marketed to increase good cholesterol. Niacin, a B vitamin, elevates HDL “but it’s not clear whether it lowers cardiac events,” according to Stephen Kopecky, a cardiologist at the Mayo Clinic in Rochester, Minnesota.

 

BusinessWeek, by Ellen Gibson, 3/5/2010

Tags: cardiac events, Cardiology, cholesterol, Dr. Stephen Kopecky, Resverlogix

You must be logged-in to the site to post a comment.

Contact Us · Privacy Policy